OncoMatch/Clinical Trials/NCT07034391
A Study Evaluating the Efficacy of PD-1 Inhibitor Combined With Denosumab and Chemotherapy in Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Patients With Driver Gene-Negative Status
Is NCT07034391 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies denosumab combined anti-PD-1 inhibitor with chemotherapy for non-small cell lung cancer.
Treatment: denosumab combined anti-PD-1 inhibitor with chemotherapy — This is an interventional study to explore the efficacy and safety of denosumab combined chemotherapy and anti-PD-1/PD-L1 inhibitor in locally advanced or metastatic NSCLC.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: ALK wild-type
Required: BRAF wild-type
Required: EGFR wild-type
Required: MET wild-type
Required: RET wild-type
Required: ROS1 wild-type
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: targeted therapy
no prior targeted therapy
Cannot have received: systemic anticancer treatment
Any previous systemic anticancer treatment for NSCLC, including chemotherapy, biologics, immunotherapy, or investigational agents
Cannot have received: bone-modifying agent (denosumab, bisphosphonates)
Prior use of denosumab or any bone-modifying agents (e.g., bisphosphonates)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify